Pipeline – HPSC BioSeed — Pioneering Placental Stem Cell Technology

Product Pipeline

HPSC Cell Technology Platform

Our proprietary HPSC platform is a comprehensive system combining placental stem cell technology and exosome technology for advanced regenerative medicine — backed by FDA IND authorization.

Proprietary Technology Portfolio

HPSC®

Placenta-Derived Maternal Stem Cell Technology

pcMSC derived from the choriodecidual membrane of the placenta (maternal origin). Exhibits powerful immune modulation and angiogenesis stimulation, making it particularly suited for inflammatory and vascular conditions. Immune Modulatio

HPSC®-b

Placenta-Derived Fetal Stem Cell Technology

pcMSC derived from the fetal side of the placenta — characterized by high tissue regeneration and cellular repair potential, with strong differentiation capacity into multiple tissue types.

HPSC®-exo

Stem Cell-Derived Exosome Technology

Functional exosomes derived from our proprietary pcMSC cultures. Features high biological activity, efficient tissue penetration, and the unique ability to cross the blood–brain barrier — enabling CNS applications.

Regulatory Status

FDA Investigational New Drug Authorization

The US FDA has approved our IND application — confirming the scientific validity and clinical potential of our placental stem cell research. This is among the most significant regulatory milestones in cell technology development.

Of all global cell technology IND applications, placental cell technology programs are exceedingly rare. Only two organizations worldwide have received FDA authorization for placental cell-based drug development:

CLINICAL TRIAL: NCT05886985

✓ IND Approved

US FDA authorization received — entered human clinical study stages.

✓ 16+ Preclinical Studies

Comprehensive preclinical safety and efficacy data package completed.

✓ Published Research

Frontiers in Immunology publication — compassionate use clinical outcomes (2022).

✓ Yahoo Finance Listed

Parent company publicly accessible: VSBC on Yahoo Finance.

Proposed Clinical Progress

Proposed Clinical Indications — 2025–2026

Proposed Clinical Progress — Indication Categories (Chinese & English)

Clinical Evidence

Preclinical Study: Acute Lung Injury (ALI/ARDS)

Animal studies investigated the therapeutic effects of HPSC pcMSC in an acute lung injury (ALI) mouse model — a preclinical model relevant to ARDS and severe COVID-19 complications. Results demonstrated significant therapeutic benefit across all measured parameters.

Significant reduction in inflammatory cell counts in bronchoalveolar lavage
Marked improvement in lung tissue condition (HE staining confirmed)
Enhanced survival outcomes vs. untreated control groups
Immunomodulatory mechanism confirmed — IL-1β, IFN-γ, IL-2, IL-6 reduced
5 severe COVID-19 compassionate-use patients — zero 28-day mortality

STUDY PARAMETERS

Model LPS-induced ALI mouse model & COVID-19 compassionate use

Endpoints Inflammatory cells, tissue histology, immune profiling, survival

Result Highlight Statistically significant improvement in all parameters (p < 0.05)

Publication Frontiers in Immunology (2022) · NCT05886985

COVID-19 Compassionate Use — Immune Marker Improvement

CRP Reduction

−78%

IL-6 Reduction

−65%

LDH Reduction

−55%

Survival (28-day)

100% (5/5)

Source: Frontiers in Immunology, 2022. n=5 severe COVID-19 patients refractory to standard treatment.

← Previous Page Next Page →